Drug Names
Foundation Medicine Nets FDA Approval for Tissue, Liquid NGS CDx for Lynparza Combo
The FDA approved FoundationOne CDx and FoundationOne Liquid for identifying BRCA1/2-mutated mCRPC patients eligible for Lynparza, Zytiga, and a steroid.
Io9 AI-Driven Digital Pathology Test Shows Potential to Inform Breast, Ovarian Cancer Therapy
Premium
The firm hopes to develop its DeepHRD digital pathology test as an alternative to costly companion diagnostics based on next-generation sequencing.
FDA Approves FoundationOne Liquid CDx to Select BRCA-Mutated mCRPC Patients for Janssen's Akeega
The FDA expanded the label to include the blood-based sequencing test as well as the tissue-based CDx, which was already approved to select patients for Akeega.
AmoyDx, Servier Partner to Develop CDx for Diffuse Glioma in China
The companies will develop a test to detect isocitrate dehydrogenase 1 and 2 gene mutations for use with Servier's investigational drug vorasidenib.
Natera, Alliance for Clinical Trials in Oncology Partner for Urothelial Cancer Study
The study will assess the use of Natera's Signatera assay in guiding treatment among people with muscle-invasive urothelial cancer after bladder removal.